Ascendis Pharma announced that the European Medicines Agency's CHMP has given a positive opinion for TransCon CNP (Navepegritid), a once-weekly treatment for achondroplasia in children aged 2 and above with open growth plates. This recommendation supports EU approval, with the European Commission's final decision expected in Q4 2026. TransCon CNP is notable for providing continuous exposure to active CNP, addressing the underlying FGFR3 signaling imbalance in achondroplasia. If approved, the drug will be marketed as YUVIWEL® in the EU, starting in Germany in early 2027, offering a new treatment option for this rare genetic growth disorder.
Ascendis Pharma (ASND) trades at USD 225.25 on Pluang as of Oct 17, 2026 21:11 WIB, down 0.60% in the last day with a market cap of $14.81 billion. The article highlights a positive CHMP opinion for TransCon CNP, which could influence investor sentiment. Despite this, Pluang order activity shows 100% selling interest at this time, reflecting cautious market behavior.
Ascendis Pharma announced that the European Medicines Agency's CHMP has issued a positive opinion recommending approval of TransCon CNP (navepegritide), a once-weekly treatment for achondroplasia in children aged two and older with open growth plates...
The European Medicines Agency's CHMP has recommended marketing authorization for Ascendis Pharma's once-weekly TransCon CNP (navepegritide) to treat achondroplasia in children aged two and older with open growth plates. This positive opinion follows ...
